Merus N.V.: Business Overview, Financials & Competitive Analysis
Merus N.V. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Acquisition by Genmab mitigates regulatory and execution risk, but value creation depends on clinical trial success for immuno-oncology pipeline candidates in competitive oncology market. Merus demonstrates strong scientific capabilities and robust partnership agreements, but faces challenges as a clinical-stage company with minimal revenue and significant cash burn. The acquisition by.
What is Merus N.V.'s industry? Merus N.V. (merus.nl) operates in Biotechnology - Immuno-Oncology. AskCyborg classifies Merus N.V. under Biotechnology - Immuno-Oncology in its company registry.
Merus is a clinical-stage immuno-oncology company developing innovative bispecific and trispecific antibody therapeutics using proprietary Biclonics® and Triclonics® platforms. The company is leveraging these technolo...
Cyborg Score thesis
Acquisition by Genmab mitigates regulatory and execution risk, but value creation depends on clinical trial success for...
Read the full analyst-debate transcript →Get the Latest Merus N.V. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeMerus N.V. Overview
Pro stress-test →Merus is a clinical-stage immuno-oncology company developing innovative bispecific and trispecific antibody therapeutics using proprietary Biclonics® and Triclonics® platforms. The company is leveraging these technologies to create multispecific cancer treatments that simultaneously target multiple pathways in tumor cells while activating the immune system.
Strategic Profile
Pro stress-test →Merus has established strategic partnerships with major pharmaceutical companies including Eli Lilly, Ono Pharmaceutical, and Betta Pharmaceuticals to fund development and provide milestone payments. As of December 2025, Merus operates as a subsidiary of Genmab A/S following an acquisition at $97 per share, removing regulatory risks and providing access to Genmab's infrastructure while maintaining focus on its pipeline of clinical-stage candidates.
Competitive Landscape
Pro stress-test →Merus competes in the bispecific antibody therapeutics space against companies developing multispecific cancer treatments. Key competitors include Genmab (now parent company), which brings scale and established market relationships, while other clinical-stage developers like Bicara Therapeutics also pursue similar multispecific approaches for oncology indications.
Industry Context
Merus N.V. operates in Biotechnology - Immuno-Oncology.
Key facts
Founded: 2003 · Headquarters: Utrecht, Netherlands · Employees: ~260 · Revenue: $56.6M · Market cap: $6.83B